Published in JAMA on March 17, 2010
Radiation Medicine Patient Registry, Loma Linda University Medical Center | NCT02436941
Study of Hypofractionated Proton Beam Radiation Therapy for Prostate Cancer | NCT00831623
Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer (2011) 1.90
Charged particle therapy--optimization, challenges and future directions. Nat Rev Clin Oncol (2013) 1.70
Proton beam and prostate cancer: An evolving debate. Rep Pract Oncol Radiother (2013) 1.48
Proton beam therapy and localised prostate cancer: current status and controversies. Br J Cancer (2013) 1.08
Caring for patients with cancer. JAMA (2010) 1.07
Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. Cancer (2012) 1.04
The clinical case for proton beam therapy. Radiat Oncol (2012) 0.90
International Conference on Advances in Radiation Oncology (ICARO): outcomes of an IAEA meeting. Radiat Oncol (2011) 0.89
Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2013) 0.86
Promise and pitfalls of heavy-particle therapy. J Clin Oncol (2014) 0.85
A 57-year-old man with a history of prostatectomy and pelvic irradiation presents with recurrent urinary tract infections, hematuria, and pelvic pain. Urology (2013) 0.81
Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials. Acta Oncol (2013) 0.80
Big Data Analytics for Prostate Radiotherapy. Front Oncol (2016) 0.80
Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensity-modulated radiation therapy. Cancer Med (2014) 0.78
Current state of the art, multimodality research and future visions for the treatment of patients with prostate cancer: consensus results from "Challenges and Chances in Prostate Cancer Research Meeting 2013". Radiat Oncol (2014) 0.78
Dose-Escalated Stereotactic Body Radiation Therapy for Prostate Cancer: Quality-of-Life Comparison of Two Prospective Trials. Front Oncol (2016) 0.75
Conventional and high-dose radiation in treating early prostate cancer. JAMA (2010) 0.75
Clinical controversies: proton therapy for prostate cancer. Semin Radiat Oncol (2013) 0.75
Prostate cancer: Patient-reported functional outcomes with radiation therapy. Nat Rev Urol (2010) 0.75
Socioeconomic factors, urological epidemiology and practice patterns. J Urol (2010) 0.75
Proton Therapy: Ever Shifting Sands and the Opportunities and Obligations within. Front Oncol (2011) 0.75
The opportunity cost of androgen suppression in locally advanced prostate cancer. Asian J Androl (2013) 0.75
Proton therapy for early stage prostate cancer: is there a case? Onco Targets Ther (2016) 0.75
Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys (2016) 0.75
Proton therapy in clinical practice. Chin J Cancer (2011) 0.75
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys (2006) 11.17
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med (2011) 7.46
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol (2008) 5.28
Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol (2008) 4.69
Bladder cancer. Lancet (2009) 4.43
Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol (2003) 4.33
Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab (2002) 3.85
Patient-reported measures of health: The Veterans Health Study. J Ambul Care Manage (2004) 3.30
Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys (2002) 3.21
Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol (2011) 3.17
Optimization of intensity-modulated radiotherapy plans based on the equivalent uniform dose. Int J Radiat Oncol Biol Phys (2002) 3.15
Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. J Clin Oncol (2008) 2.72
Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys (2006) 2.69
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol (2008) 2.68
Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol (2012) 2.61
Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys (2003) 2.58
Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys (2007) 2.55
Bladder cancer. J Natl Compr Canc Netw (2013) 2.46
Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol (2009) 2.40
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol (2008) 2.20
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 2.19
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer (2008) 2.16
Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys (2010) 2.14
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer (2013) 2.10
American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy (2012) 2.03
Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol (2002) 2.00
Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol (2011) 1.99
Analysis of data errors in clinical research databases. AMIA Annu Symp Proc (2008) 1.99
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol (2007) 1.95
Management of complications of prostate cancer treatment. CA Cancer J Clin (2008) 1.91
Proton beams to replace photon beams in radical dose treatments. Acta Oncol (2003) 1.87
Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol (2012) 1.87
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol (2012) 1.86
PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys (2005) 1.83
A free program for calculating EUD-based NTCP and TCP in external beam radiotherapy. Phys Med (2007) 1.81
What do you mean, a spot?: A qualitative analysis of patients' reactions to discussions with their physicians about pulmonary nodules. Chest (2013) 1.79
Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2011) 1.75
Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. J Natl Cancer Inst (2009) 1.75
Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys (2009) 1.71
Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys (2005) 1.70
Comparing the health status of VA and non-VA ambulatory patients: the veterans' health and medical outcomes studies. J Ambul Care Manage (2004) 1.70
Proton vs carbon ion beams in the definitive radiation treatment of cancer patients. Radiother Oncol (2010) 1.65
Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. Int J Radiat Oncol Biol Phys (2006) 1.62
Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol (2004) 1.61
Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys (2006) 1.60
Validation of a web-based predictive nomogram for ipsilateral breast tumor recurrence after breast conserving therapy. J Clin Oncol (2010) 1.59
Racial differences in how patients perceive physician communication regarding cardiac testing. Med Care (2002) 1.58
Permanent alopecia after cranial irradiation: dose-response relationship. Int J Radiat Oncol Biol Phys (2004) 1.58
Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest (2004) 1.57
Quantification of mediastinal and hilar lymph node movement using four-dimensional computed tomography scan: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys (2007) 1.56
A technique of partial breast irradiation utilizing proton beam radiotherapy: comparison with conformal x-ray therapy. Cancer J (2007) 1.55
Chest wall radiotherapy: middle ground for treatment of patients with one to three positive lymph nodes after mastectomy. Int J Radiat Oncol Biol Phys (2009) 1.55
From physical dose constraints to equivalent uniform dose constraints in inverse radiotherapy planning. Med Phys (2003) 1.52
Treatment 'mismatch' in early prostate cancer: do treatment choices take patient quality of life into account? Cancer (2008) 1.51
Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol (2003) 1.51
Racial differences in cardiac catheterization as a function of patients' beliefs. Am J Public Health (2004) 1.47
Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer. J Oncol Pract (2014) 1.47
The use and QA of biologically related models for treatment planning: short report of the TG-166 of the therapy physics committee of the AAPM. Med Phys (2012) 1.46
Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancer. Urol Oncol (2007) 1.44
Secondary carcinogenesis in patients treated with radiation: a review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects. Radiat Res (2007) 1.44
Can axillary dissection be avoided in patients with sentinel lymph node metastasis? J Surg Oncol (2006) 1.43
Improving the response choices on the veterans SF-36 health survey role functioning scales: results from the Veterans Health Study. J Ambul Care Manage (2004) 1.42
Proton beam therapy and accountable care: the challenges ahead. Int J Radiat Oncol Biol Phys (2012) 1.42
The Titanic and the Iceberg: prostate proton therapy and health care economics. J Clin Oncol (2007) 1.41
Long-term durability of PSA failure-free survival after radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2002) 1.40
Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention? BJU Int (2010) 1.40
Using patient-reported outcomes to assess and improve prostate cancer brachytherapy. BJU Int (2014) 1.39
Case records of the Massachusetts General Medicine. Weekly clinicopathological exercises. Case 9-2003. An 18-year-old man with back and leg pain and a nondiagnostic biopsy specimen. N Engl J Med (2003) 1.38
Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol (2009) 1.35
Bladder cancer. J Natl Compr Canc Netw (2009) 1.32
The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer (2011) 1.29
Racial differences in trust and regular source of patient care and the implications for prostate cancer screening use. Cancer (2009) 1.28
Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children. Cancer J (2005) 1.28
Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer (2007) 1.28